The Most Read Articles in August in Interventional Cardiology

01- Best Revascularization Strategy in Patients with Left Ventricular Deterioration

Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy. 

Read also HERE

02- SOLACI Renewed Authorities During the SOLACI-CACI 2021 Congress

After a massive event attended by thousands of people, the Latin American Society of Interventional Cardiology renewed its authorities for the 2021-2023 term.

Read also HERE

03- New Markers of Aortic Stenosis Define Asymptomatic Patients

Asymptomatic aortic stenosis has been keeping us in tense stillness. However, there are new markers capable of identifying patients that might benefit from earlier intervention. In this regard, cardiovascular magnetic resonance (CMR) has been gaining its well-deserved place in cardiology and now more specifically in aortic stenosis. 

Read also HERE

04- Anticoagulation with Heparin in Non-Critical COVID-19

In non-severe COVID-19 patients, an initial therapeutic strategy with heparin increases the chance of survival after discharge and reduces the need for respiratory and cardiovascular support compared against usual thromboprophylaxis doses. 

Read also HERE

05- SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Daniel Zanuttini (Arg.) presents “Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection”. This is the 8th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences and opinions, to keep advancing our knowledge in interventional cardiology. 

Read also HERE

06- ESC 2021 | MASTER DAPT: Dual Antiplatelet Therapy After Coronary Angioplasty in Patients at High Bleeding Risk

Courtesy of Dr. José Álvarez.

In patients at high bleeding risk with drug-eluting stents, the duration of dual antiplatelet therapy has been subjected to ongoing review.

Read also HERE

07- The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES.

Read also HERE

08- Watch Again our Webinar on Challenges in TAVR: Evidence, Complex Anatomies, Durability

Watch Again our Webinar on “Challenges in TAVR: Evidence, Complex Anatomies, Durability”.

Read also HERE

09- Complete Revascularization after Pharmacoinvasive Strategy

Patients initially receiving pharmacoinvasive strategy for ST elevation myocardial infarction (STEMI) also presenting multivessel disease consistently benefit from complete revascularization. This benefit is similar to that of primary PCI.  

Read also HERE

10- Heparin Anticoagulation in Critically Ill COVID-19 Patients: Results that Differ from the Rest

In critically ill COVID-19 patients, an initial strategy of anticoagulation with heparin did not result in any benefit compared with standard prophylactic treatment.

Read also HERE

Would you like to receive a weekly summary of the most recent scientific articles?